Neurocrine Biosciences Raises FY24 Net Product (valbenazine) Revenue Outlook To $2.30B-$2.32B
Portfolio Pulse from Benzinga Newsdesk
Neurocrine Biosciences has increased its fiscal year 2024 net product revenue outlook for valbenazine to a range of $2.30 billion to $2.32 billion.
October 30, 2024 | 11:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neurocrine Biosciences has raised its FY24 revenue outlook for valbenazine, indicating strong sales expectations and potential stock price appreciation.
The increase in revenue outlook suggests strong demand and sales performance for valbenazine, which is likely to positively influence investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100